Advertisement
Lipella Pharma Soars 48% After FDA Oks IND For LP-310 For Oral Lichen Planus
(RTTNews) - Biotechnology company Lipella Pharmaceuticals Inc. (LIPO) announced Friday that the U.S. Food and Drug Administration (FDA) has approved an Investigational New Drug (IND) application for a multi-center, phase-2a, dose-escalation clinical trial.
The trial will assess the safety and efficacy of LP-310 in patients with symptomatic oral lichen planus (OLP), a highly morbid condition with no effective treatment.
In March 2023, Lipella created a five-member Scientific Advisory Board in Oral Health, made up of a group of highly regarded experts in oral medicine, to focus on the development of LP-310.
read more
Lipella Pharma Announces Top Line Results In Phase 2A Trial Of LP-10 For Hemorrhagic Cystitis
Biotechnology company Lipella Pharmaceuticals Inc. (LIPO) announced top line results for its recently completed Phase 2a clinical trial evaluating the safety and efficacy of its drug candidate LP-10 for Hemorrhagic Cystitis, a rare but highly morbid disease for which there are currently no FDA approved treatments.
RTTNews
|
984 दिनों पहले
European Shares Seen Mostly Lower In Cautious Trade
European stocks are seen opening flat to slightly lower on Monday as investors react to the Trump administration's immigration crackdown on H-1B visas and shift focus to a slew of U.S. economic data as well as speeches by Fed Chair Jerome Powell and other Fed officials due this week for additional clues on the future path of interest rates.
RTTNews
|
1घंटे 43 मिनट पहले
China Leaves Key Interest Rates Unchanged
The People's Bank of China left its benchmark interest rates unchanged for the fourth straight month despite key indicators suggesting economic slowdown. The PBoC kept its one-year loan prime rate unchanged at 3.0 percent. Similarly, the five-year LPR, the benchmark for mortgage rates, was retained at 3.50 percent. The decision came in line with expectations.
RTTNews
|
1घंटे 54 मिनट पहले
Sensex, Nifty Little Changed; IT Stocks Tumble After H-1B Visa Fee Increase
Indian shares were little changed on Monday despite U.S. President Donald Trump's decision to impose a hefty $100000 fee on H-1B visas to protect American jobs.
RTTNews
|
2घंटे 42 मिनट पहले
Australian Market Trims Early Gains In Mid-market
The Australian stock market is trimming its early gains in mid-market trading on Monday, but adding to the gains in the previous session, following the broadly positive cues from Wall Street on Friday. The benchmark S&P/ASX 200 index is moving above the 8,800.00 level, with gains across most sectors led by mining and financial stocks.
RTTNews
|
3घंटे 51 मिनट पहले
Asian Markets Trade Mixed
Asian stock markets are trading mixed on Monday, following the positive cues from Wall Street on Friday, as the recent interest rate cut decision by the US Fed and the forecast by Fed officials of two more rate cuts this year but just one next year, continue to lift market sentiment. However, major currencies in the region weakened against the US dollar. Asian markets closed mixed on Friday.
RTTNews
|
4घंटे 11 मिनट पहले
Sensex, Nifty Set To Open Lower After Trump's Visa Crackdown
Indian shares look set to open lower on Monday, with tech stocks likely to be in focus after U.S. President Donald Trump signed an executive order slapping an additional fee on H-1B visa holders, potentially impacting profitability and prompting companies to rethink hiring strategies.
RTTNews
|
4घंटे 47 मिनट पहले
Japanese Market Sharply Higher
The Japanese stock market is trading sharply higher on Monday, reversing the losses in the previous session, following the broadly positive cues from Wall Street on Friday, with the Nikkei 225 nearly 600 points to well above the 45,600 level, with gains across most sectors led by exporters and technology stocks.
RTTNews
|
5घंटे 3 मिनट पहले
